In these, it was described that the administration of exogenous CX3CL1 into the striatum reduced the microglial activation and loss of neurons in a Parkinson’s disease rat model based on intrastriatal administration of 6-hydroxydopamine [53]. This evidence concerns the gene CX3CL1 and Parkinson disease.